22/09/2025Published by Fondazione Gianni Bonadonna at 22/09/2025Categories Events UncategorizedAtezolizumab, paclitaxel and bevacizumab as first line therapy in triple-negative breast cancer
15/09/2025Published by Fondazione Gianni Bonadonna at 15/09/2025Categories Events UncategorizedPyrotinib plus a new antibody-drug conjugate in HER+ breast cancer
08/09/2025Published by Fondazione Gianni Bonadonna at 08/09/2025Categories Events UncategorizedFirst-line camizestrant for ESR-1 mutated advanced breast cancer
01/09/2025Published by Fondazione Gianni Bonadonna at 01/09/2025Categories Events UncategorizedPerioperative durvalumab in gastric and gastroesophageal junction cancer
25/08/2025Published by Fondazione Gianni Bonadonna at 25/08/2025Categories Events UncategorizedLonger survival with tarlatamab in small-cell lung cancer
04/08/2025Published by Fondazione Gianni Bonadonna at 04/08/2025Categories Events UncategorizedTrastuzumab deruxtecan or ramucirumab plus paclitaxel in gastric cancer
28/07/2025Published by Fondazione Gianni Bonadonna at 28/07/2025Categories Events UncategorizedCemiplimab in high risk cutaneous squamous-cell carcinoma
21/07/2025Published by Fondazione Gianni Bonadonna at 21/07/2025Categories Events UncategorizedPembrolizumab plus enzalutamide and androgen deprivation therapy in prostate cancer
14/07/2025Published by Fondazione Gianni Bonadonna at 14/07/2025Categories Events UncategorizedInavosilib in PIK3CA-mutated advanced breast cancer
